A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma
Latest Information Update: 23 Mar 2026
At a glance
- Drugs SYS 6055 (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 23 Mar 2026 New trial record